Literature DB >> 10446103

High prevalence of NSAID enteropathy as shown by a simple faecal test.

J A Tibble1, G Sigthorsson, R Foster, D Scott, M K Fagerhol, A Roseth, I Bjarnason.   

Abstract

BACKGROUND: The diagnosis of non-steroidal anti-inflammatory drug (NSAID) induced enteropathy is difficult, requiring enteroscopy or the use of four day faecal excretion of (111)In labelled white cells. AIMS: To assess faecal calprotectin (a non-degraded neutrophil cytosolic protein) as a method for diagnosing NSAID enteropathy.
METHODS: Single stool faecal calprotectin concentrations were compared with the four day faecal excretion of (111)In labelled white cells in 47 patients taking NSAIDs. The prevalence and severity of NSAID enteropathy was assessed using this method in 312 patients (192 with rheumatoid arthritis, 65 with osteoarthritis, 55 with other conditions) taking 18 different NSAIDs.
RESULTS: The four day faecal excretion of (111)In white cells correlated significantly with faecal calprotectin concentrations. In the group of 312 patients on NSAIDs faecal calprotectin concentrations were significantly higher than in controls, the prevalence of NSAID enteropathy being 44%. The prevalence and severity of NSAID enteropathy was independent of the particular type or dose of NSAID being taken or other patient variables.
CONCLUSIONS: Assay of faecal calprotectin provides a simple practical method for diagnosing NSAID enteropathy in man. Forty four per cent of patients receiving these drugs had NSAID induced enteropathy when assessed by this technique; 20% of these had comparable levels of inflammation to that previously reported in patients with inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446103      PMCID: PMC1727647          DOI: 10.1136/gut.45.3.362

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  30 in total

1.  Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin.

Authors:  I Dale; P Brandtzaeg; M K Fagerhol; H Scott
Journal:  Am J Clin Pathol       Date:  1985-07       Impact factor: 2.493

2.  Increased intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral nonsteroidal anti-inflammatory drug therapy?

Authors:  R T Jenkins; P J Rooney; D B Jones; J Bienenstock; R L Goodacre
Journal:  Br J Rheumatol       Date:  1987-04

3.  Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis?

Authors:  A W Segal; D A Isenberg; V Hajirousou; S Tolfree; J Clark; M L Snaith
Journal:  Br J Rheumatol       Date:  1986-05

4.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.

Authors:  C P Armstrong; A L Blower
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

5.  Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs.

Authors:  I Bjarnason; G Zanelli; P Prouse; P Smethurst; T Smith; S Levi; M J Gumpel; A J Levi
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

6.  Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine.

Authors:  I Bjarnason; P Williams; P Smethurst; T J Peters; A J Levi
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

7.  Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs.

Authors:  I Bjarnason; P Williams; A So; G D Zanelli; A J Levi; J M Gumpel; T J Peters; B Ansell
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

8.  Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs.

Authors:  A J Collins; J A Du Toit
Journal:  Br J Rheumatol       Date:  1987-08

9.  Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans.

Authors:  I Bjarnason; G Zanelli; T Smith; P Prouse; P Williams; P Smethurst; G Delacey; M J Gumpel; A J Levi
Journal:  Gastroenterology       Date:  1987-09       Impact factor: 22.682

10.  Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage.

Authors:  M J Langman; L Morgan; A Worrall
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-02
View more
  76 in total

Review 1.  Ileitis: when it is not Crohn's disease.

Authors:  Steven Dilauro; Nancy F Crum-Cianflone
Journal:  Curr Gastroenterol Rep       Date:  2010-08

2.  Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis.

Authors:  Matthew L Stoll; Marilynn Punaro; Ashish S Patel
Journal:  J Rheumatol       Date:  2011-10       Impact factor: 4.666

3.  Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury.

Authors:  Chen Huang; Bin Lu; Yi-Hong Fan; Lu Zhang; Ning Jiang; Shuo Zhang; Li-Na Meng
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 4.  Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests?

Authors:  Francesco Costa; Maria Gloria Mumolo; Santino Marchi; Massimo Bellini
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

5.  Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity.

Authors:  William E Ruff; Carina Dehner; Woo J Kim; Odelya Pagovich; Cassyanne L Aguiar; Andrew T Yu; Alexander S Roth; Silvio Manfredo Vieira; Christina Kriegel; Olamide Adeniyi; Melissa J Mulla; Vikki M Abrahams; William W Kwok; Ruth Nussinov; Doruk Erkan; Andrew L Goodman; Martin A Kriegel
Journal:  Cell Host Microbe       Date:  2019-06-18       Impact factor: 21.023

6.  Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs.

Authors:  E Smecuol; J C Bai; E Sugai; H Vazquez; S Niveloni; S Pedreira; E Mauriño; J Meddings
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

7.  Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation.

Authors:  Raffaele Pezzilli; Alessandra Barassi; Antonio M Morselli-Labate; Lorenzo Fantini; Paola Tomassetti; Davide Campana; Riccardo Casadei; Sergio Finazzi; Gianvico Melzi d'Eril; Roberto Corinaldesi
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

8.  Calprotectin as a diagnostic tool for inflammatory bowel diseases.

Authors:  Marianthi Chatzikonstantinou; Panagiotis Konstantopoulos; Spyros Stergiopoulos; Konstantinos Kontzoglou; Christos Verikokos; Despina Perrea; Dimitris Dimitroulis
Journal:  Biomed Rep       Date:  2016-09-07

9.  The Gut Mucosal Firewall and Functional Medicine.

Authors:  Jeffrey Bland
Journal:  Integr Med (Encinitas)       Date:  2016-08

Review 10.  Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy.

Authors:  Laurence Maiden
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.